BioXcel Therapeutics (BTAI) Short Interest Ratio & Short Volume $1.82 -0.17 (-8.54%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.02 (+1.37%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BioXcel Therapeutics Short Interest DataBioXcel Therapeutics (BTAI) has a short interest of 221,300 shares, representing 8.08% of the float (the number of shares available for trading by the public). This marks a -33.04% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1.16 million shares to cover all short positions.Current Short Interest221,300 sharesPrevious Short Interest330,500 sharesChange Vs. Previous Month-33.04%Dollar Volume Sold Short$471,369.00Short Interest Ratio0.1 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares3,206,000 sharesFloat Size2,740,000 sharesShort Percent of Float8.08%Today's Trading Volume83,619 sharesAverage Trading Volume1,159,326 sharesToday's Volume Vs. Average7% Short Selling BioXcel Therapeutics? Sign up to receive the latest short interest report for BioXcel Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBTAI Short Interest Over TimeBTAI Days to Cover Over TimeBTAI Percentage of Float Shorted Over Time Remove Ads BioXcel Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2025221,300 shares $471,369.00 -33.0%8.1%0.1 $2.13 2/28/2025330,500 shares $713,880.00 +16.2%12.1%0.1 $2.16 2/15/2025284,500 shares $657,195.00 +13.5%11.0%2 $2.31 1/31/2025250,700 shares $1.31 million -84.3%9.7%2.1 $5.22 1/15/20251,600,000 shares $554,400.00 +98.1%N/A1.1 $0.35 12/31/2024807,700 shares $301,999.03 -23.1%N/A1 $0.37 12/15/20241,050,000 shares $432,705.00 +16.8%N/A1.7 $0.41 11/30/2024898,700 shares $367,298.69 +44.0%N/A1.4 $0.41 11/15/2024624,100 shares $354,676.03 +79.8%N/A1.2 $0.57 10/31/2024347,100 shares $231,446.28 -39.8%N/A0.7 $0.67 Get the Latest News and Ratings for BTAI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/2024576,400 shares $327,913.96 +11.6%N/A1.2 $0.57 9/30/2024516,400 shares $315,004.00 -26.0%N/A0.9 $0.61 9/15/2024697,600 shares $474,368.00 +2.5%N/A1.1 $0.68 8/31/2024680,500 shares $418,507.50 -6.9%N/A1.2 $0.62 8/15/2024731,200 shares $497,216.00 -9.4%N/A1.2 $0.68 7/31/2024807,300 shares $904,176.00 +28.9%N/A1.2 $1.12 7/15/2024626,100 shares $763,842.00 -61.4%N/A1 $1.22 6/30/20241,620,000 shares $2.07 million +8.7%N/A2.8 $1.28 6/15/20241,490,000 shares $2.04 million +0.7%N/A2.9 $1.37 5/31/20241,480,000 shares $2.68 million -9.2%N/A2.6 $1.81 5/15/20241,630,000 shares $3.36 million +8.7%N/A2.8 $2.06 4/30/20241,500,000 shares $3.78 million -28.2%N/A1 $2.52 4/15/20242,090,000 shares $5.75 million -16.1%N/A1.4 $2.75 3/31/20242,490,000 shares $7.02 million -20.7%10.5%1.7 $2.82 3/15/20243,140,000 shares $8.42 million -20.9%14.6%2.1 $2.68 2/29/20243,970,000 shares $12.62 million -46.8%18.7%2.6 $3.18 2/15/20247,460,000 shares $26.78 million +203.3%35.2%4.9 $3.59 1/31/20242,460,000 shares $7.92 million -17.5%11.9%2.1 $3.22 1/15/20242,980,000 shares $7.84 million +0.3%14.4%1.1 $2.63 12/31/20232,970,000 shares $8.76 million +3.5%14.7%1 $2.95 12/15/20232,870,000 shares $9.30 million -16.6%14.2%0.9 $3.24 11/30/20233,440,000 shares $13.07 million -32.3%17.0%1.1 $3.80 11/15/20235,080,000 shares $22.35 million -12.6%25.1%1.6 $4.40 10/31/20235,810,000 shares $23.33 million +16.9%28.8%1.9 $4.02 10/15/20234,970,000 shares $15.56 million +38.8%24.6%3.6 $3.13 9/30/20233,580,000 shares $9.06 million -24.6%17.7%2.4 $2.53 9/15/20234,750,000 shares $15.87 million +8.0%23.5%1.6 $3.34 8/31/20234,400,000 shares $16.63 million -34.8%21.8%1.5 $3.78 8/15/20236,750,000 shares $27.95 million -4.1%33.5%2.3 $4.14 7/31/20237,040,000 shares $64.35 million -18.8%35.0%2.7 $9.14New “Trump” currency proposed in DC (Ad)According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. When you see what could happen – I think you’ll be excited. 7/15/20238,670,000 shares $89.30 million +69.0%43.1%3.5 $10.30 6/30/20235,130,000 shares $34.17 million +12.3%25.5%2.2 $6.66 6/15/20234,570,000 shares $98.26 million +22.9%22.7%8.3 $21.50 5/31/20233,720,000 shares $66.74 million +11.0%18.5%6.2 $17.94 5/15/20233,350,000 shares $91.22 million -5.4%16.7%6.5 $27.23 4/30/20233,540,000 shares $72.99 million -5.1%17.7%6.9 $20.62 4/15/20233,730,000 shares $69.90 million +3.6%18.6%7.4 $18.74 3/31/20233,600,000 shares $67.18 million +21.2%18.3%7.2 $18.66 3/15/20232,970,000 shares $58.21 million +5.7%15.1%6.3 $19.60 2/28/20232,810,000 shares $89.70 million +8.9%14.7%8 $31.92 2/15/20232,580,000 shares $84.29 million +5.3%13.5%7.6 $32.67 1/31/20232,450,000 shares $69.87 million +5.6%12.9%7.4 $28.52 1/15/20232,320,000 shares $67.14 million -3.3%12.2%8.1 $28.94 12/30/20222,400,000 shares $51.55 million +10.1%12.6%9.4 $21.48 12/15/20222,180,000 shares $44.04 million -4.4%11.5%9 $20.20 11/30/20222,280,000 shares $37.78 million -3.4%12.0%10.2 $16.57 11/15/20222,360,000 shares $38.00 million -6.7%12.4%10.9 $16.10 10/31/20222,530,000 shares $31.85 million -4.2%13.3%11.7 $12.59 10/15/20222,640,000 shares $27.06 million -5.7%13.9%11.1 $10.25 9/30/20222,800,000 shares $33.10 million -2.1%14.7%10.4 $11.82 9/15/20222,860,000 shares $37.95 million -2.4%15.0%8.5 $13.27 8/31/20222,930,000 shares $40.08 million -0.3%15.4%6.9 $13.68 8/15/20222,940,000 shares $44.86 million +7.7%15.5%6.1 $15.26 7/31/20222,730,000 shares $42.15 million -5.5%14.4%5 $15.44 7/15/20222,890,000 shares $48.70 million -19.7%15.2%5 $16.85 6/30/20223,600,000 shares $47.52 million -9.3%19.0%4 $13.20 6/15/20223,970,000 shares $39.14 million -1.2%20.9%4.4 $9.86 5/31/20224,020,000 shares $47.03 million -2.9%21.2%4.8 $11.70 5/15/20224,140,000 shares $48.60 million +5.3%21.8%5.2 $11.74 4/30/20223,930,000 shares $51.52 million -3.0%20.7%5.3 $13.11 4/15/20224,050,000 shares $63.10 million +97.6%21.4%5.7 $15.58 3/31/20222,050,000 shares $42.87 million +9.0%10.8%3.3 $20.91 3/15/20221,880,000 shares $28.31 million +0.5%9.9%6.1 $15.06 2/28/20221,870,000 shares $34.24 million +10.7%9.9%6.5 $18.31 2/15/20221,690,000 shares $31.38 million -5.1%8.9%5.4 $18.57 1/31/20221,780,000 shares $30.08 million -0.6%9.4%5.5 $16.90 1/15/20221,790,000 shares $34.91 million +3.5%9.4%5.9 $19.50 12/31/20211,730,000 shares $35.17 million -11.7%9.1%5.7 $20.33 12/15/20211,960,000 shares $42.59 million -1.0%10.3%6.7 $21.73 11/30/20211,980,000 shares $45.40 million +10.6%10.4%6.9 $22.93 11/15/20211,790,000 shares $48.71 million -4.3%9.4%6.6 $27.21 10/29/20211,870,000 shares $54.49 million +8.1%9.9%7.5 $29.14 10/15/20211,730,000 shares $46.87 million -6.0%9.1%6.7 $27.09 9/30/20211,840,000 shares $55.84 million -3.2%9.7%6.9 $30.35 9/15/20211,900,000 shares $56.51 million -6.9%10.0%5.4 $29.74 8/31/20212,040,000 shares $60.08 million -8.1%10.8%5.4 $29.45 8/13/20212,220,000 shares $54.59 million -5.9%11.8%5.9 $24.59 7/30/20212,360,000 shares $60.39 million -9.9%12.6%6.1 $25.59 7/15/20212,620,000 shares $70.11 million -11.8%14.0%6.8 $26.76 6/30/20212,970,000 shares $86.31 million +2.1%16.9%7.7 $29.06New “Trump” currency proposed in DC (Ad)According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. When you see what could happen – I think you’ll be excited. 6/15/20212,910,000 shares $108.60 million -5.5%19.2%7.8 $37.32 5/28/20213,080,000 shares $101.73 million -3.1%20.3%7.8 $33.03 5/14/20213,180,000 shares $96.67 million -5.6%21.0%7.3 $30.40 4/30/20213,370,000 shares $116.27 million -7.7%22.3%7.1 $34.50 4/15/20213,650,000 shares $127.57 million +9.0%N/A7 $34.95 3/31/20213,350,000 shares $137.69 million -9.7%21.4%6.1 $41.10 3/15/20213,710,000 shares $174.33 million +2.8%23.8%6.5 $46.99 2/26/20213,610,000 shares $199.09 million +1.1%23.4%6.7 $55.15 2/12/20213,570,000 shares $230.62 million +5.6%23.1%6.8 $64.60 1/29/20213,380,000 shares $156.33 million -7.9%23.0%6.6 $46.25 1/15/20213,670,000 shares $198.55 million +10.2%25.0%7.7 $54.10 12/31/20203,330,000 shares $163.90 million +4.4%22.7%6.9 $49.22 12/15/20203,190,000 shares $147.89 million -2.5%21.8%7.2 $46.36 11/30/20203,270,000 shares $145.81 million +10.9%22.3%7.2 $44.59 11/15/20202,950,000 shares $160.13 million +4.2%20.1%6.2 $54.28 10/30/20202,830,000 shares $133.15 million +22.0%22.4%5.2 $47.05 10/15/20202,320,000 shares $120.41 million -13.8%18.3%3.5 $51.90 9/30/20202,690,000 shares $116.64 million +17.0%21.3%3.9 $43.36 9/15/20202,300,000 shares $111.09 million +6.5%18.2%3.3 $48.30 8/31/20202,160,000 shares $88.02 million -10.4%17.1%3.1 $40.75 8/14/20202,410,000 shares $90.42 million -14.2%20.7%3.5 $37.52 7/31/20202,810,000 shares $127.46 million +30.1%22.3%4.6 $45.36 7/15/20202,160,000 shares $109.08 million -3.6%20.6%4.3 $50.50 6/30/20202,240,000 shares $118.74 million +137.3%21.3%4.8 $53.01 6/15/2020944,000 shares $44.91 million +39.9%9.0%2.1 $47.57 5/29/2020674,800 shares $31.42 million -13.6%6.4%1.4 $46.56 5/15/2020781,000 shares $36.83 million -8.4%7.4%1.4 $47.16 4/30/2020852,400 shares $31.54 million +30.0%8.1%1.2 $37.00 4/15/2020655,500 shares $15.68 million +8.4%6.3%1 $23.92 BTAI Short Interest - Frequently Asked Questions What is BioXcel Therapeutics' current short interest? Short interest is the volume of BioXcel Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 221,300 shares of BTAI short. 8.08% of BioXcel Therapeutics' shares are currently sold short. Learn More on BioXcel Therapeutics' current short interest. Which institutional investors are shorting BioXcel Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioXcel Therapeutics: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for BioXcel Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.08% of BioXcel Therapeutics' floating shares are currently sold short. Is BioXcel Therapeutics' short interest increasing or decreasing? BioXcel Therapeutics saw a decline in short interest in March. As of March 15th, there was short interest totaling 221,300 shares, a decline of 33.0% from the previous total of 330,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is BioXcel Therapeutics' float size? BioXcel Therapeutics currently has issued a total of 3,206,000 shares. Some of BioXcel Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BioXcel Therapeutics currently has a public float of 2,740,000 shares. How does BioXcel Therapeutics' short interest compare to its competitors? 8.08% of BioXcel Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to BioXcel Therapeutics: Equillium, Inc. (2.08%), CytoMed Therapeutics Limited (2.09%), CalciMedica, Inc. (1.39%), Longeveron Inc. (5.96%), VYNE Therapeutics Inc. (1.19%), Q32 Bio Inc. (22.85%), DURECT Co. (2.94%), Pulmatrix, Inc. (1.04%), Annovis Bio, Inc. (19.51%), Cara Therapeutics, Inc. (1.93%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short BioXcel Therapeutics stock? Short selling BTAI is an investing strategy that aims to generate trading profit from BioXcel Therapeutics as its price is falling. BTAI shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioXcel Therapeutics? A short squeeze for BioXcel Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BTAI, which in turn drives the price of the stock up even further. How often is BioXcel Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BTAI, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies EQ Short Squeeze GDTC Short Squeeze CALC Short Squeeze LGVN Short Squeeze VYNE Short Squeeze QTTB Short Squeeze DRRX Short Squeeze PULM Short Squeeze ANVS Short Squeeze CARA Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BTAI) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
